Source comparison
PT-141 for Libido Enhancement: Treatment Comparison
PT-141 (Bremelanotide) MC3R/MC4R agonist. Central desire pathway activation 45–60 minutes 50–80% increase in SSEs vs baseline in HSDD populations Nausea in 40% of users (decreases with tolerance); requires injection Best for central desire deficits independent
This comparison does not assign a generated winner or score.
- PT-141 (Bremelanotide)
- MC3R/MC4R agonist. Central desire pathway activation
- 45–60 minutes
- 50–80% increase in SSEs vs baseline in HSDD populations
- Nausea in 40% of users (decreases with tolerance); requires injection
- Best for central desire deficits independent of vascular function or hormones
- PDE5 Inhibitors (sildenafil, tadalafil)
- Phosphodiesterase-5 inhibition. Genital vasodilation
- 30–60 minutes
- Not effective for HSDD without arousal/performance component
- Does not address desire. Only physical capacity for arousal
- Best for arousal/performance deficits with intact desire
- Testosterone Replacement
- Androgen receptor activation. Systemic hormonal effect
- 2–6 weeks
- Effective only when testosterone deficiency confirmed (<30 ng/dL)
- Requires baseline deficiency; side effects include virilization in women
- Best when lab-confirmed hypogonadism is root cause
- Flibanserin (Addyi)
- 5-HT1A agonist / 5-HT2A antagonist. Serotonin modulation
- Daily use, 4–8 weeks for effect
- Modest SSE increase (0.5–1.0/month); 10% achieve meaningful benefit
- Requires daily use; alcohol interaction contraindicated
- Best for patients preferring daily oral over on-demand injection
- Bupropion
- Dopamine/norepinephrine reuptake inhibitor. Off-label for SSRI-induced dysfunction
- 1–2 weeks
- Effective for SSRI-induced sexual dysfunction in 50–70% of cases
- Not FDA-approved for sexual dysfunction; requires daily use
- Best as adjunct to ongoing SSRI therapy when libido loss is medication-induced
- PT-141 for libido enhancement occupies the on-demand, centrally-acting niche. It works when the problem is neural desire signaling rather than vascular performance or hormone deficiency. For patients where multiple mechanisms contribute to sexual dysfunction, combination approaches (e.g., testosterone for baseline hormonal support plus PT-141 for on-demand desire augmentation) may offer synergistic benefit, though clinical trial data on combination protocols remain limited.